Macquarie described Neuren Pharmaceuticals shares as a standout in the biotech industry and set a price target of $18.60 on ...

This ASX 300 stock is having a good session on Wednesday. Let's see why investors are bidding its shares higher ...

Nvidia (NASDAQ: NVDA) investors have been very happy in recent years. Since 2020, shares have increased in value by roughly 1 ...

Analysts from Morgan Stanley believe the humanoid robot market could be worth $5 trillion by 2035. Musk believes Tesla could ...

These 2 ASX growth shares could deliver big returns, in my opinion. Here’s why I’m excited about them right now.

Citi currently has a buy rating and $2.70 price target on its shares. Another ASX dividend stock that has been given a buy ...

Dylan Evans from Catapult Wealth has provided his views on two popular ASX REITs, Goodman Group (ASX: GMG) and BWP Trust (ASX ...

The ASX dividend share is one of the leaders in the sector, in my opinion. It's expecting to pay a distribution per security ...

Aurizon Holdings has struck a new deal with materials giant BHP. Macquarie believes this is good news for Aurizon shares.

The Vanguard Australian Shares Index ETF (ASX: VAS) is a very popular investment. But, there are other attractive ASX ETFs to ...

Macquarie has released a new note on Cochlear Ltd (ASX: COH) shares following the company's FY25 profit guidance change.